Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.
复制标题
DOI：
10.1007/s00277-017-3003-0
复制
发表时间：
2017-07
影响因子：
3.5
通讯作者：
Rummel M
中科院分区：
文献类型：
--
作者：
Weiss L;Melchardt T;Egle A;Hopfinger G;Hackl H;Greil R;Barth J;Rummel M
肥胖是癌症发展的一个众所周知的危险因素，但其对疾病进程的影响仍然存在争议。我们在StiL（惰性淋巴瘤研究组）NHL 1试验的亚组分析中调查了502例惰性非霍奇金淋巴瘤或套细胞淋巴瘤患者的体重指数（BMI）对总生存期（OS）的影响。我们通过ROC计算和Youden指数分析确定22.55 kg/m2为临界值，并将患者分为“低BMI”和“高BMI”。与低BMI组（66.2%）相比，高BMI组（82.2%）的5年OS显著更长（HR 0.597; 95%CI 0.370-0.963; p = 0.034）。在多变量分析中BMI也是OS的独立预后因素（HR 0.541; 95%CI 0.332-0.883; p = 0.014）。值得注意的是，存在B症状的患者的BMI显著低于不存在B症状的患者（p = 0.025）。BMI显著影响惰性非霍奇金淋巴瘤和套细胞淋巴瘤的OS，这可能受到B症状对BMI的影响。本文的在线版本（doi：10.1007/s 00277 -017-3003-0）包含补充材料，可供授权用户使用。
Obesity is a well-known risk factor for the development of cancer, but its influence on the course of disease is still controversial. We investigated the influence of body mass index (BMI) on overall survival (OS) in 502 patients with indolent non-Hodgkin’s lymphoma or mantle cell lymphoma in a subgroup analysis of the StiL (Study Group Indolent Lymphomas) NHL1 trial. We defined a cut-off of 22.55 kg/m2 by ROC calculation and Youden Index analysis and stratified patients into “low BMI” and “high BMI”. Five-year OS was significantly longer in the high BMI group (82.2%) when compared to that of the low BMI group (66.2%) (HR 0.597; 95%CI 0.370–0.963; p = 0.034). BMI was also an independent prognostic factor for OS in multivariate analysis (HR 0.541; 95%CI 0.332–0.883; p = 0.014). Of note, patients had a significantly lower BMI in the presence than patients in the absence of B-symptoms (p = 0.025). BMI significantly impacts on OS in indolent non-Hodgkin’s lymphoma and mantle cell lymphoma, which may be influenced by the effect of B-symptoms on BMI. The online version of this article (doi:10.1007/s00277-017-3003-0) contains supplementary material, which is available to authorized users.